2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

503. Clonal Hematopoiesis, Aging, and Inflammation: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Bioinformatics, Computational Biology, Treatment Considerations, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Infectious Diseases, Viral, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

3139 Lipid-mediated programmed cell death evasion in Tet2-deficent HSPCs and macrophages

Isak William Tengesdal, PhD, Thais Pereira Aljentera2, Siddhartha Jaiswal, MD/PhD3
1 Department of Pathology, Stanford University, Stanford, California, United States
2 Department of Pathology, Stanford University, Stanford, California, United States
3 Department of Pathology, Stanford University, Stanford, California, United States, Insititue for Stem Cell Biology & Regenerative Medicine, Stanford University, Stanford, California, United States

Clonal hematopoiesis of indeterminate potential (CHIP) is a pre-malignant state in which mutations in hematopoietic stem and progenitor cells (HSPCs) lead to a selective advantage within the hematopoietic compartment and hyperinflammatory myeloid cells. Paradoxically, a hyperinflammatory phenotype should be coupled with an increase in programmed cell death (PCD), however, our understanding of this relationship in CHIP remains incomplete. All PCD pathways, while different in executors, ultimately converge on plasma membrane rupture (PMR) facilitated by oligomerization of the plasma membrane protein NINJ1. Here, we demonstrate that altered lipid metabolism following loss of TET2, in human and murine HSPCs and macrophages, protects against PMR during pyroptosis and ferroptosis.

 

To start, we longitudinally assessed the kinetics of pyroptosis in CRISPR edited AAVS1 and TET2-deficient THP-1 macrophages through activation of the NLRP3 inflammasome at 1,4, and 24 hours. Expectedly, TET2-deficient THP-1 macrophages exhibited increased IL-1β secretion (p<0.05) and capsase-1 activation (p<0.05), accompanied by elevated GSDMD-NT cleavage up to 24 hours following LPS/Nigericin or LPS/ATP stimulation. Strikingly, cell death was markedly lower at all timepoints in TET2-deficient compared to AAVS1 THP-1 macrophages, as detected by LDH and membrane impermeant CellTox DNA dye. We confirmed these observations in both murine and human primary HSPCs and macrophages. Consistently, using primary cell models, activation of NLRP3 resulted in significantly increased IL-1β production and significantly decreased LDH release in TET2-deficient cells. Taken together these data suggest TET2-deficient HSPCs and macrophages, despite exhibiting over activation of NLRP3 are resistant to pyroptosis-mediated PCD in both murine and human CHIP experimental models.

 

Next, we performed RNA-Seq on unstimulated murine BMDMs from Tet2-deficient and WT littermate controls. Pathway enrichment analysis revealed DEGs in Tet2-deficient mice in genes associated with lipid metabolism, namely sphingolipid metabolism, cholesterol metabolism and fatty acid metabolism. Thus, we performed lipidomics on Tet2-deficient and AAVS1 THP-1 macrophages (N=3, pooled independent experiments) which reveled elevated lipid classes such as cholesterol esters (CER), ceramides (CE), and sphingomyelin (SM) (3-5 Log2 fold change) in Tet2-deficient cells. This was accompanied by increased free cholesterol levels in Tet2-deficient macrophages as detected by Filipin dye.

 

Our lipidomics data also revealed an 8-fold higher MUFA/PUFA ratio in Tet2-deficient THP-1 cells. Therefore, we sought to assess whether ferroptosis, an iron-dependent cell death pathway mediated by peroxidated lipids, was disrupted as elevated PUFAs are known to drive ferroptosis. Using the ferroptosis inducer, RSL3, loss of TET2 was significantly protective against ferroptosis-driven PMR in THP-1 macrophages, CD34+ HSCs & CD34+-derived macrophages, and murine cKit+ & BMDMs as determined by LDH release. Interestingly, the lipid peroxidation dye BODIPY 581/591 revealed no difference between control and TET2-deficient macrophages following RSL3 stimulation suggesting the stark reduction in LDH release is agnostic of fatty acid composition between genotypes.

 

Mechanistically, our existing lipid analyses revealed markedly elevated CER, CE, SM, and free cholesterol. As these lipid classes are known to be enriched in lipid rafts, we hypothesized that lipid rafts may disrupt NINJ1 oligomerization in PCD. To test this, AAVS1 or TET2-deficient THP-1 cells were treated with LPS/Nigericin or RSL3. Following stimulation, NINJ1 was cross-linked to preserve oligomerization enabling us to determine the extent of NINJ1-mediated PMR and western blots were ran for NINJ1 on pooled precipitated supernatants and cell lysates. Importantly, AAVS1 and TET2-deficient THP-1 exhibited similar levels of NINJ1 monomers. Remarkably, we observed extensive formation of high order NINJ1 oligomers (3-mer→N-mer) in AAVS1 THP-1 cells, whereas high order NINJ1 oligomers were not detected in TET2-deficient THP-1 cells following pyroptosis or ferroptosis stimulation. This observation suggests the formation of high order NINJ1 oligomers necessary for PMR are disrupted in TET2-deficient macrophages.

 

Collectively, these findings propose a novel mechanism by which altered lipid metabolism in TET2-CHIP disrupts NINJ1-mediated PMR in HSPCs and macrophages.

Isak William Tengesdal, PhD: Olatec Therapeutics - Current equity holder in private company